Cancer Drug Shop BioVex Markets Legacy Technology for shRNA Delivery | GenomeWeb

By Doug Macron

Looking to eke out value from technology developed before a corporate restructuring, cancer drug developer BioVex has been marketing vectors, originally designed for drug delivery, for RNAi-based target validation applications.

The technology comprises replication-defective herpes simplex viruses that express shRNAs and can be delivered to the nervous system both in vitro and in vivo.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CBC Marketplace commissions DNA testing of chicken sandwiches at Subway and other fast-food chains.

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

In Genome Research this week: algorithm to tease out strains from metagenomic sequences, drug resistance mechanisms in cancer cells, and more.

Variants in the IFITM3 gene affect inflammatory response to infection, UPI reports.